When IBL Healthcare Ltd (IBLHL) sat down with analysts in November, the message was a mix of celebration and caution. The health and wellness distributor has just posted its strongest year on record, riding the same wave of deregulated prices and volume recovery that lifted much of Pakistan’s regulated healthcare sector in 2025. But the first quarter of financial year 2026 already hints at a slower tempo — and a future in which growth will depend less on price resets and more on a deliberate push into artificial sweeteners, cold and flu remedies, and new wellness categories.
At the heart of the strategy is a bold target: to triple the size of the company by 2030, anchored in Stevia-based sweeteners and over-the-counter cold, cough and flu brands, with women’s health and holistic adult nutrition as the next frontiers. The content in this publication is expensive to produce. But unlike other journalistic outfits, business publications have to cover the very organizations that directly give them advertisements. Hence, this large source of revenue, which is the lifeblood of other media houses, is severely compromised on account of Profit’s no-compromise policy when it comes to our reporting. No wonder, Profit has lost multiple ad deals, worth tens of millions of rupees, due to stories that held big businesses to account. Hence, for our work to continue unfettered, it must be supported by discerning readers who know the value of quality business journalism, not just for the economy but for the society as a whole.To read the full article, subscribe and support independent business journalism in Pakistan
